Anthem Biosciences Limited (BOM:544449)

Market Cap	425.04B
Revenue (ttm)	21.29B +15.1%
Net Income	5.92B +31.1%
EPS	10.43 +29.7%
Shares Out	n/a
PE Ratio	71.82
Forward PE	58.55
Dividend	2.00 (0.27%)
Ex-Dividend Date	Jun 25, 2026

Volume	8,286
Open	752.65
Previous Close	751.30
Day's Range	749.40 - 759.55
52-Week Range	579.45 - 873.25
Beta	n/a
Analysts	Strong Buy
Price Target	879.43 (+16.51%)
Earnings Date	Aug 5, 2026

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Commercial Physical and Biological Research
• Founded: 2006
• Employees: 2,282
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544449

Financial Performance

In fiscal year 2026, Anthem Biosciences's revenue was 21.29 billion, an increase of 15.09% compared to the previous year's 18.50 billion. Earnings were 5.92 billion, an increase of 31.14%.

Analyst Summary

According to 7 analysts, the average rating for 544449 stock is "Strong Buy." The 12-month stock price target is ₹879.43, which is an increase of 16.51% from the latest price.

Price Target

₹879.43

(16.51% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 13, 2026

Data Sources Report a data error